Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Series: Technology appraisal guidance -- no.35
Publisher: National Institute for Clinical Excellence
Published: 2002
Place of publication: London
Language: eng
Notes: Review date: January 2005.

Title from cover.